New FDA-Approved Treatment for RKD

The FDA has approved Gazyva® (obinutuzumab) for adults and children ages 2 and older with idiopathic nephrotic syndrome that began in childhood and is frequently relapsing (FRNS) or steroid-dependent (SDNS). More information coming soon. Please visit our Patient Navigation tool for support.

RESOURCES

/

FIND A SPECIALIST

/

CONTACT

Destiny Lalonde

Associate Director, Content and Creative Strategy

Destiny (Des) Lalonde serves as NephCure’s Associate Director of Content and Creative Strategy. Since joining the team in November 2022, Destiny has a passionate commitment to serving patients and families affected by rare kidney disease. Destiny immerses herself in learning, writing, and crafting content tailored to their needs while gaining newfound knowledge about NephCure’s patient community and making important connections to ensure each journey is filled with hope and guidance. Known for her proactive and empathetic approach, she eagerly embraces new challenges and continuously seeks innovative ways to educate and support the rare kidney disease community.

Destiny, a lifelong Southern California native, graduated in 2021 with a B.A. in Communications from California State University, Fullerton. Following a brief career detour as a private investigator, she now pursues her passion for writing novels and poetry, exploring new culinary destinations, and spending quality time with her partner and her fur-child, Hermes.

Fullerton, CA

Related News

NEWS

NephCure Celebrates C3G Awareness Day on September 25, 2026

NEWS

NephCure Specialist of the Month: Dr. Rupali Avasare

NEWS

Making History on Capitol Hill: Record Advocates Unite for NephCure’s Largest Hill Day Ever

NEWS

NephCure Specialist of the Month: Dr. Fahad Aziz

Sign up to get NephCure’s latest updates.

SIGN UP
This field is for validation purposes and should be left unchanged.